Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials

BACKGROUND: A review of therapies for advanced cancers licenced by the EMA between 2009 and 2013 concluded that for more than half of these drugs there was little evidence of overall survival or quality of life benefit. Recent years have witnessed a growing number of licensed second-line pharmacothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Connock, Martin, Armoiry, Xavier, Tsertsvadze, Alexander, Melendez-Torres, G. J., Royle, Pamela, Andronis, Lazaros, Clarke, Aileen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485098/
https://www.ncbi.nlm.nih.gov/pubmed/31023244
http://dx.doi.org/10.1186/s12885-019-5507-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485098/
https://www.ncbi.nlm.nih.gov/pubmed/31023244
http://dx.doi.org/10.1186/s12885-019-5507-6

Ejemplares similares